ClinicalTrials.gg
RecruitingNCT06348108Updated Mar 13, 2026

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of Talquetamab and Iberdomide in Multiple Myeloma, Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Alfred Chung, MD. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Alfred Chung, MD · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing talquetamab in Multiple Myeloma — 20 open to participants now, 27 under way, 6 of them phase 3. talquetamab · Multiple Myeloma.

Planned enrollment
20th of 30
32 · median 50
Started
2025
with 6 others
Phase 1
6 of 30
4 open now
Primary completion
2027-07
later than 7 of 26 live
Registered
14th of 30
by date
Lead sponsor
1 of 30
Alfred Chung, MD

Among the 30 studies testing talquetamab in Multiple Myeloma, this one is the 20th largest by planned enrollment, is one of 7 that started in 2025, is one of 6 in phase 1, reaches primary completion later than 7 of the 26 other live ones, and was the 14th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

20 of the 30 studies testing talquetamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About talquetamab

talquetamab: first FDA approval 2023 (TALVEY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing talquetamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). There is currently a significant unmet need for patients with relapsed or refractory multiple myeloma (RRMM) who are triple class refractory and have been exposed to B-cell maturation antibody (BCMA) targeted therapy. These patients currently have limited treatment options and poor survival. Talquetamab is an FDA approved drug that can bring T-cells to the myeloma cell, resulting in myeloma cell death. Iberdomide is an investigational drug and works by targeting and destroying proteins that help myeloma cancer cells to survive. Dexamethasone is a corticosteroid, is similar to a natural hormone produced by the adrenal glands to reduce inflammation (swelling, heat, redness, and pain) and is used to in helping to treat certain types of cancer including myeloma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess safety of the combination of talquetamab (Tal), iberdomide (Iber) and dexamethasone (Dex) in patients with triple class exposed (TCE) RRMM. (Phase 1b-dose escalation (DE)).

II. To assess dose limiting toxicity (DLT) and determine the recommended phase 2 dose (RP2D) of the combination of Tal, Iber and Dex administered in 28-day cycles in patients with TCE RRMM. (Phase 1b-DE).

III. To further assess safety of RP2D of the combination of Tal, Iber and Dex administered in 28-day cycles in patients with TCE RRMM Len-refractory, and having received >= 2 prior lines of therapy. (Phase 1b-expansion (Exp)).

IV. To assess overall response rate (ORR) in patients with TCE RRMM, Len-refractory, and having received ≥ 2 prior lines of therapy. (Phase 1b-Exp).

SECONDARY OBJECTIVES:

I. To assess ORR, and to determine minimal residual disease (MRD) negative (-) rates in patients achieving ≥ very good partial remission (VGPR).

II. To assess toxicity (incidence of adverse events (AEs), serious AEs (SAEs), and treatment discontinuation due to toxicity) and safety (physical examination findings, vital signs, and clinical laboratory evaluations) in patients with RRMM.

III. Describe changes in health-related quality of life (HRQoL) using the European Organization for Research and Treatment of Cancer (C30) -Quality of Life questionnaire (QLQ) (EORTC-QLQ-C30), EORTC QLQ Oral Health 15 (OH-15) and EORTC QLQ-Multiple Myeloma Questionnaire (MY20)).

EXPLORATORY OBJECTIVES:

I. To assess serum cytokines levels with treatment of the combination of Tal, Iber and Dex and the predictive values of response, cytokine release syndrome (CRS) and other adverse events.

II. To assess changes in immune cells in blood and bone marrow with treatment of the combination of Tal, Iber and Dex.

III. To determine the efficacy of combination of Tal, Iber and Dex defined as Objective Response Rate (ORR) and achieving complete response (CR) and MRD (-) status and correlation between mass spectroscopy and bone marrow (BM) MRD assessments.

OUTLINE: This is a dose-escalation study of Iber followed by a dose-expansion study.

Participants receive Tal in cycle 1 then all 3 drugs will be given in combination in cycle 2 but may be continued at the discretion of the investigator. Cycles repeat every 28 days for as long as there is clinical benefit as determined by the Investigator. Study treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the participant, noncompliance with study requirements, intercurrent illness, or closure of the study by the Sponsor.

After completion of study treatment, patients are followed up at 30 days every 8 weeks for up to 3 years or until progression or initiation of subsequent therapy.

03

Conditions studied

  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age.
  2. Has a prior history of (h/o) MM (based on International Myeloma Working Group (IMWG) criteria) and now has evidence of MM. RRMM of progressive disease as defined by the IMWG 2006 and 2016 criteria (Kumar at al).
  3. Specific criteria for dose escalation and dose expansion:

    1. Phase 1 dose escalation: patients will be required to have TCE RRMM (including a proteasome inhibitor (PI) (≥ 2 cycles or 2 months of treatment), an immunomodulatory drug (IMiD)) (≥ 2 cycles or 2 months of treatment) and a CD38 antibody (≥ 2 cycles or 2 months of treatment) after receiving ≥ 3 . Prior BCMA exposure is allowed. (Subjects with discontinued PI/IMiD/Cluster of differentiation 38 (CD38) therapy due to severe adverse event after \< 2 months are allowed)
    2. Dose expansion cohort: RRMM patients will be lenalidomide refractory, TCE (exposed to IMiD, PI and CD38 antibody therapy (≥ 2 cycles or 2 months of treatment for each) and have received ≥ 2 prior lines of therapy. Prior BCMA targeted therapy is allowed, not required. (Subjects with discontinued PI/IMiD/CD38 therapy due to severe adverse event after \< 2 months are allowed. Lenalidomide refractory is defined as having evidence of progressive disease on lenalidomide (≥ 10 mg or greater, ≥ 21 days/28) or within 60 days of stopping lenalidomide therapy.)
  4. Has defined as at least 1 of the following:

    1. Serum M-protein ≥ 0.5 g/dL (dose escalation) and 1.0 g/dL (dose expansion cohorts)
    2. Urine M-protein ≥ 200 mg/24 hours
    3. Serum free light chain (FLC) assay: involved FLC assay ≥ 10 mg/dL (≥ 100 mg/L) AND an abnormal serum FLC ratio (\< 0.26 or > 1.65). (Can be used to fulfill the inclusion criteria of measurable disease in patients who do not have measurable disease by M-protein).
  5. Has an (ECOG) performance status of 0 or 1.
  6. Has adequate baseline organ function, as demonstrated by the following:

    1. Calculated > 30 mL/min as assessed by the Cockcroft-Gault equation, Modification of Diet in Renal Disease () equation (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2015) or as assessed by 24-hour urine collection.
    2. Serum ≤ 1.5 mg/dL, excluding Gilbert's.
    3. (AST) and alanine transaminase (ALT) ≤ 2.5 × institutional upper limit normal ().
    4. Total serum calcium (corrected for serum albumin) or ionized calcium within normal limits (WNL) (treatment of hypercalcemia is allowed and patients may enroll if hypercalcemia returns to WNL with standard treatment).
  7. Has adequate baseline hematologic function, as demonstrated by the following:

    1. (ANC) ≥ 1.0 x 10\^9/L (myeloid growth factors must not have been administered within 7 days (14 days for extended 1/2-life products).
    2. ≥ 8 g/dL (red blood cell transfusions permitted provided the anemia is disease-related).
    3. count ≥ 100 x 10\^9/L and no platelet transfusions during the 7 days before first dose (without transfusions). (Dose expansion cohorts will be allowed to have platelets counts ≥ 75 x 10\^9/L with no platelet transfusions during the prior 7 days).
  8. Must have at least 2 negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test result obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second within 24 hours prior to initiating therapy if the patient is a female of (FCBP; defined as a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally for at least 24 consecutive months).
  9. Men and women of childbearing potential must agree to not donate sperm and eggs (ova and oocytes) throughout study therapy and for 3 months after the last treatment.
  10. Men and women agree to use acceptable methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 3 months after the last treatment with study treatment.

    1. Women of childbearing potential must agree to 2 methods of reliable birth control simultaneously while receiving study treatment and until 100 days after last dose of study treatment: one highly effective form of contraception (tubal ligation, intrauterine device, hormonal [oral, injectable, transdermal patches, vaginal rings or implants] or partner's vasectomy, and 1 additional effective contraceptive method (male latex or synthetic condom, diaphragm or cervical cap).
    2. Males must agree to always use a latex or synthetic condom during any sexual contact with females of .
  11. All patients should be encouraged to be fully vaccinated prior to initiation of therapy including being up-to-date on vaccines against pneumococcus, yearly influenza, Coronavirus disease (COVID) booster(s), and any age appropriate vaccine. are not allowed while on study treatment or within 4 weeks of starting treatment.
  12. Has provided signed before initiation of any study-specific procedures or treatment.
  13. Must agree to, and be capable of, adhering to the study visit schedule and other protocol requirements, including follow-up for overall survival.

Exclusion criteria

Exclusion Criteria:

  1. Has persistent toxicities (grade ≥ 2; per National Cancer Institute (NCI) (CTCAE) version 5.0) from previous anticancer therapy (excluding alopecia which is permitted and excluding grades 2 and 3 laboratory abnormalities (including hematologic abnormalities) if participants are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies.
  2. Has NCI CTCAE grade ≥ 3 peripheral neuropathy from any etiology or grade ≥ 2 peripheral neuropathy with pain.
  3. Has received treatment with cytotoxic (alkylators) within 3 weeks, biologic (IMiDs/PIs) within 2 weeks, targeted therapies (monoclonal antibodies) within 4 weeks, chimeric antigen receptor (CAR) T-cell (CAR-T)or stem cell transplant therapy within 3 months or any novel therapy within 5- 1/2 lives of therapy.
  4. Has had radiation therapy within 14 days of first dose of study therapy, unless less than 5% marrow exposure, then no limit.
  5. Has had any prior GPRC5D targeted bispecific antibody therapy or GPRC5D CAR-T therapy or has had previous treatment with Iber.
  6. Has any active or uncontrolled infection including any viral, bacterial or fungal infection; and/or , active hepatitis (Hep) C and active Hep B ( (HB) surface antigen (HBsAg) (+), HB core antigen (HBcAb) (+) or (+) Hep B deoxyribonucleic acid (DNA) by polymerase chain reaction (pcr), Hep C ribonucleic acid (RNA) (+) by pcr. Patients who have received Intravenous immunoglobulin therapy (IVIG) replacement therapy may have (+) HBcAb results from the IVIG therapy. These patients can enroll if Hep B DNA by pcr test is negative. These patients need to be on antiviral therapy and be monitored for hepatitis B virus (HBV) DNA throughout study therapy per local guidelines and as clinically indicated.
  7. Has an additional active that may confound the assessment of the study endpoints. If the patient has a past cancer history (active malignancy within 2 years before study entry) with substantial potential for recurrence, this must be discussed with the sponsor/investigator before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: nonmelanoma skin cancer and carcinoma in situ (including transitional cell carcinoma, cervical cancer, anal carcinoma, ductal carcinoma in situ (DCIS) and melanoma in situ), any cancer resected with curative intent, low-grade cancer not requiring therapy.
  8. Is pregnant or breast feeding.
  9. Has clinically significant cardiovascular disease including, albeit not limited to:

    1. Uncontrolled or any Class 3 or 4 congestive heart failure
    2. Uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months before study entry
    3. Uncontrolled hypertension or clinically significant arrhythmias not controlled by medication.
  10. Has active POEMS (polyneuropathy, organomegaly, endocrinopathy/edema, monoclonal-protein, skin syndrome), amyloid light (AL) amyloidosis, primary plasma cell leukemia or active central nervous system (CNS) or parenchymal/ myeloma.
  11. Has uncontrolled, clinically significant organ dysfunction that in the opinion of the investigator would put the patient at significant risk for toxicity from study therapy.
  12. Has recent major surgery within 4 weeks or significant gastrointestinal (GI) disease that would interfere with GI absorption of oral medications.
  13. Has a condition, including disease, requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days before study therapy administration. Inhaled or topical steroids and adrenal replacement doses \<10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  14. Has received treatment with allogeneic stem cell transplant within 6 months before the first dose of study treatment and if > 6 months from allogeneic stem cell transplantation (alloSCT) must be off all immunosuppression and without evidence of active (GVHD).
  15. Uncontrolled epilepsy or new/recent seizure activity within 6 months of study entry.
  16. administered within 4 weeks prior to study therapy.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Cohort: Dose Level (DL) 1 (Talquetamab, Iberdomide, Dexamethasone) - Starting Dose

    Participants receive 0.8 mg/kg Talquetamab (Tal) subcutaneously (SQ) over 1-3 minutes every 2 weeks (days 1 and 15 of each cycle), 0.75 mg Iberdomide orally (PO) once a day (QD) on days 1-21 of each 28-day cycle, and 20-40mg of Dexamethasone PO weekly, but may be continued at the discretion of the investigator. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, skeletal x-ray, CT, Positron Emission Tomography (PET)/CT, or MRI, tissue and blood sample collection throughout the study.

    Biological: Talquetamab · Drug: Iberdomide · Drug: Dexamethasone · Procedure: Bone Marrow Biopsy

  • Experimental
    Dose Escalation Cohort: DL 2 (Talquetamab, Iberdomide, Dexamethasone)

    Participants receive 0.8 mg/kg Talquetamab (Tal) subcutaneously (SQ) over 1-3 minutes every 2 weeks (days 1 and 15 of each cycle), 1.0 mg Iberdomide orally (PO) once a day (QD) on days 1-21 of each 28-day cycle, and 20-40mg of Dexamethasone PO weekly, but may be continued at the discretion of the investigator. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, skeletal x-ray, CT, Positron Emission Tomography (PET)/CT, or MRI, tissue and blood sample collection throughout the study.

    Biological: Talquetamab · Drug: Iberdomide · Drug: Dexamethasone · Procedure: Bone Marrow Biopsy

  • Experimental
    Dose Expansion Cohort (Talquetamab, Iberdomide, Dexamethasone)

    Participants receive the recommended phase 2 dose of Iberdomide in combination with Talquetamab and 20-40mg of Dexamethasone which may be continued at the discretion of the investigator. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, imaging scans, tissue and blood sample collection throughout the study.

    Biological: Talquetamab · Drug: Iberdomide · Drug: Dexamethasone · Procedure: Bone Marrow Biopsy

Interventions

  • BiologicalTalquetamab

    Given subcutaneously (SQ)

    Also known as: Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, DuoBody Antibody JNJ-64407564

  • Given orally (PO)

    Also known as: CELMoD, CC-220, 1323403-33-3

  • Given PO

    Also known as: Decadron, DexPak, Hemady

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy

06

What researchers measure

Primary outcomes

  1. Proportion of participants reporting treatment-emergent adverse events (AEs) (Dose Escalation Cohorts)

    Safety will be evaluated for the population of participants who received at least one dose of study drug. Treatment-emergent AEs will be graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 1 cycle (Cycles are 28 days in length)

  2. Proportion of participants experiencing Dose-Limiting Toxicity (DLTs) (Dose Escalation Cohorts)

    Maximum tolerated dose (MTD) will be defined as the highest dose at which no more than one instance of DLT is observed among 6 participants treated.

    Time frame: Up to 1 cycle (Cycles are 28 days in length)

  3. Recommended phase 2 dose (RP2D) (Dose Escalation Cohorts)

    RP2D will be defined as the MTD to be evaluated in the expansion cohort based on safety and preliminary activity of at least 2 dose levels (6 patients treated/dose level).

    Time frame: Up to 1 cycle (Cycles are 28 days in length)

  4. Proportion of participants experiencing Dose-Limiting Toxicity (DLTs) (Dose Expansion Cohort)

    The frequency, type, and severity (grade) of each DLT will be reported

    Time frame: Up to 3 years

  5. Objective response rate (ORR) (Dose Expansion Cohort)

    ORR will be defined as all responses greater than or equal to a partial response (PR) (i.e., PR, very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) per International Myeloma Working Group (IMWG) definition). Under Simon's two-stage design, final efficacy evaluation for the primary endpoint will calculate the uniformly minimum variance unbiased estimator, p-value and 95% CI for the response rates.

    Time frame: Up to 3 years

Secondary outcomes

  1. Objective response rate (ORR) (Dose Escalation Cohorts)

    ORR will be defined as all responses greater than or equal to a partial response (i.e., PR, VGPR, CR, or sCR per IMWG definition). Will be summarized using frequency and percentage, along with 95% CIs.

    Time frame: Up to 3 years

  2. Number of participants achieving VGPR or CR and MRD (negative (-)) response

    MRD will be defined as achieving ≥ VGPR and MRD (-) response will be defined as having \< 1 multiple myeloma clone per 100,000 bone marrow cells (10-5) by next-generation sequencing (NGS) (clono sequence (seq); 10-5). Will be reported for the entire population and for those treated at the MTD.

    Time frame: Up to 3 years

  3. Proportion of participants with treatment-related adverse events

    Toxicity will be measured by CTCAE version 5.0; cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS) will be assessed according to the American Society for Transplantation and Cellular Therapy guidelines; neurological treatment-emergent adverse events that are not assessed as ICANS should be graded per CTCAE version 5.0 and managed by per institutional guidelines.

    Time frame: Up to 3 years

  4. Changes in scores on the European Organization for Research and Treatment of Cancer - Quality of Life questionnaire (EORTC-QLQ-C30) over time

    The functional domains measure the quality of life in Physical functioning, Role functioning, Emotional functioning, Cognitive functioning, Social functioning. Scores consists of responses to items with responses ranging from 1="Not at all" to 4="Very Much". The raw score is calculated by estimating the mean of the items that make up each domains with a resulting total range of 1 - 4. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the functional domains represents a high level of functioning.

    Time frame: Up to 3 years

  5. Changes in scores on the EORTC QLQ- Multiple Myeloma Questionnaire (EORTC-QLQ-M20) over time

    The EORTC QLQ-MY20 is a 20-item questionnaire that is designed to measure the quality of life of people with multiple myeloma. Scores consists of responses to items addressing multiple myeloma-related symptoms and quality of life issues with responses ranging from 1="Not at all" to 4="Very Much". The raw score is calculated by estimating the mean of the items that make up each domains with a resulting total range of 1 - 4. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the functional domains represents a high level of functioning.

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
  • University of Calfornia, San Francisco
    San Francisco, California 94143, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 201 non-industry phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 24 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2024
First posted
Apr 4, 2024
StartActual
Jul 28, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2029
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06348108
Lead sponsor
Alfred Chung, MD
Responsible party
Alfred Chung, MD (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Apr 4, 2024
Start date
Jul 28, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Mar 13, 2026

Study contacts

UCSF Hematopoietic Malignancies Clinical Trial Recruitment
Contact
HDFCCC.Heme@ucsf.edu
877-827-3222
Alfred Chung, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Talquetamab · Iberdomide · Dexamethasone

Start the discussion